Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The production suspension impacts commercial and clinical trial supply
Upon closing, the Quakertown business will become an independent company called Microsize
He will be responsible for ensuring that every dose of medication that ACG Inspection’s pharmaceutical and nutraceutical partners provide is manufactured and delivered exactly as intended
This agreement is truly remarkable for achieving greater objectives in the projects and addressing larger problems
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
Subscribe To Our Newsletter & Stay Updated